Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Turning Point Therapeutics Inc. TPTX

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of...

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:TPTX)

Fundamentals Snapshot (NDAQ:TPTX)

Current News (NDAQ:TPTX)

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Business Wire 3 days ago

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

GlobeNewswire 11 days ago

Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

GlobeNewswire July 27, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HMTV, MANT, PCSB, TPTX

PR Newswire July 11, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX

PR Newswire July 6, 2022

Shareholder Alert - The M&A Class Action Firm is Investigating the Merger - MANT, TPTX, BHVN, MN, HMTV, CVET

PR Newswire July 5, 2022

TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders

Business Wire July 5, 2022

TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX

Business Wire July 5, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, PLD, RADA

PR Newswire June 27, 2022

Opinion & Analysis (NDAQ:TPTX)

Clinical Catalysts Impending for California-Based Biopharma

Streetwise Reports March 19, 2020

Bullboard Posts (NDAQ:TPTX)

Thanks for the tip Jack, just sold with A great profit

doubled my self in one day, i am out and going to dinner
armordeck - June 3, 2022